Neurologic Dysfunction is one of the main factors contributing to poor outcomes in cardiac surgery patients, except for heart failure. Atherosclerosis of the aorta, a history of cerebral infarction, and cervical artery disease are common clinical risk factors for cerebral neurological dysfunction after cardiac surgery. Results of preclinical studies suggested that Angong Niuhuang Pills (ANPs), a traditional Chinese patent medicine, including realgar, cinnabaris, Bovis Calculus, artificial Moschus, and powdered buffalo horn extract, decreased infarct volume and cerebral edema, and presented anti- atherosclerosis and cardio-protective effects in clinical and preclinical studies. The PANDA X trial is designed as a pilot study to explore the safety and efficacy of ANP in patients with moderate-to-severe neurologic dysfunction after cardiovascular surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
Angong Niuhuang Pill (ANP) (3 g/pill, 1 pill/day for 5 days)
Blank control
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
changes in the NIHSS score
a National Institutes of Health Stroke Scale (NIHSS) score ranging from 10 to 20
Time frame: after 14 days of randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.